株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の個別化医療市場:技術、市場シェア、産業予測

Global Personalised Medicine Market - Market share and Industry Forecast to 2024

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 675303
出版日 ページ情報 英文 240 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
世界の個別化医療市場:技術、市場シェア、産業予測 Global Personalised Medicine Market - Market share and Industry Forecast to 2024
出版日: 2018年08月02日 ページ情報: 英文 240 Pages
概要

当レポートでは、世界の個別化医療市場について調査し、産業および市場の概要、治療分野・エンドユーザー・用途・地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査概要

  • 世界の個別化医療市場:発展と変遷
  • 市場の定義と範囲
  • 産業構造
  • 市場分析
  • 予測分析
  • 戦略分析
    • 投資 vs 導入モデル
    • 全方位的産業分析
    • ファイブフォース分析
    • シーソー分析
    • 消費者分析と主な購入基準
  • 競合分析
    • 主要戦略と分析
    • 市場シェアおよび上位企業の分析
  • 戦略提言と総論
    • 地域別の投資機会
    • 新規分野の市場機会
    • 急成長市場の投資機会

第3章 市場の決定要因

  • 促進要因
  • 阻害要因
  • 市場機会
  • 課題

第4章 個別化医療市場:治療分野別

  • 市場の定義と範囲
  • 意思決定支援データベース & 推計手法
  • 市場の比較分析
  • 市場機会の分析
  • 市場区分
    • 腫瘍
    • 神経
    • 心臓
    • ウイルス性疾患
    • 精神科
    • その他

第5章 個別化医療市場:エンドユーザー別

  • 市場の定義と範囲
  • 意思決定支援データベース & 推計手法
  • 市場の比較分析
  • 市場機会の分析
  • 市場区分
    • 病院
    • 分子診断・検査機関
    • 学術機関・臨床ケア・研究機関
    • 受託開発機関
    • バイオ・ヘルスインフォマティクス企業
    • その他

第6章 個別化医療市場:用途別

  • 市場の定義と範囲
  • 意思決定支援データベース & 推計手法
  • 市場の比較分析
  • 市場機会の分析
  • 市場区分
    • コンパニオン診断
    • バイオマーカー同定
    • ヘルスインフォマティクス
    • 臨床研究

第7章 競合環境

  • 主な戦略
    • 合併・買収の一覧
    • 合弁事業の一覧
    • 発売製品の一覧
    • 事業提携の一覧

第8章 地域分析

  • 意思支援決定データベース・推計手法
  • 市場セグメントの比較分析
  • 市場機会のマトリクス
  • 地域区分
    • 北米(米国、カナダ)
    • 欧州(英国、フランス、ドイツ、スペインなど)
    • アジア太平洋(中国、インド、日本、オーストラリアなど)
    • その他の地域(ラテンアメリカ、中東・アフリカ)

第9章 企業プロファイル

  • ABBOTT LABORATORIES
  • ASURAGEN INCORPORATED
  • ASTRA ZENECA PLC
  • BECTON, DICKINSON AND COMPANY
  • BIOGEN, INC.
  • GE HEALTHCARE
  • GLAXOSMITHKLINE PLC.
  • ILLUMINA INCORPORATED
  • MERCK & COMPANY, INC.
  • NOVARTIS AG
  • PFIZER INC.
  • QIAGEN INC.
  • ROCHE HOLDING AG
  • SIEMENS HEALTHCARE
  • VERTEX PHARMACEUTICALS INC

図表リスト

図表

LIST OF TABLES

  • 1. GLOBAL PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA 2015-2024 ($ MILLION)
  • 2. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 3. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 4. GLOBAL CARDIOLOGY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 5. GLOBAL ANTIVIRAL MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 6. GLOBAL PSYCHIATRY MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 7. GLOBAL OTHERS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 8. GLOBAL PERSONALIZED MEDICINE MARKET BY END USER 2015-2024 ($ MILLION)
  • 9. GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 10. GLOBAL MOLECULAR DIAGNOSTIC LABORATORIES AND TESTING FACILITIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 11. GLOBAL ACADEMIC INSTITUTES, CLINICAL CARE AND RESEARCH LABORATORIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 12. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 13. GLOBAL BIO AND HEALTH INFORMATICS COMPANIES MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 14. GLOBAL OTHERS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 15. GLOBAL PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 16. GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 17. GLOBAL BIOMARKER IDENTIFICATION MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 18. GLOBAL HEALTH INFORMATICS MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 19. GLOBAL CLINICAL RESEARCH MARKET BY GEOGRAPHY 2015-2024 ($ MILLION)
  • 20. NORTH AMERICA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 21. EUROPE PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 22. ASIA PACIFIC PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 23. REST OF THE WORLD PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 24. NORTH AMERICA PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA 2015-2024 ($ MILLION)
  • 25. EUROPE PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA 2015-2024 ($ MILLION)
  • 26. ASIA PACIFIC PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA 2015-2024 ($ MILLION)
  • 27. REST OF THE WORLD PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA 2015-2024 ($ MILLION)
  • 28. NORTH AMERICA PERSONALIZED MEDICINE MARKET BY END USER 2015-2024 ($ MILLION)
  • 29. EUROPE PERSONALIZED MEDICINE MARKET BY END USER 2015-2024 ($ MILLION)
  • 30. ASIA PACIFIC PERSONALIZED MEDICINE MARKET BY END USER 2015-2024 ($ MILLION)
  • 31. REST OF THE WORLD PERSONALIZED MEDICINE MARKET BY END USER 2015-2024 ($ MILLION)
  • 32. NORTH AMERICA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 33. EUROPE PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 34. ASIA PACIFIC PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 35. REST OF THE WORLD PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 36. UNITED STATES PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 37. CANADA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 38. UK PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 39. GERMANY PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 40. FRANCE PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 41. SPAIN PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 42. ROE PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 43. INDIA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 44. CHINA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 45. JAPAN PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 46. AUSTRALIA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 47. ROAPAC PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 48. LATIN AMERICA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)
  • 49. MENA PERSONALIZED MEDICINE MARKET BY APPLICATION 2015-2024 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ONCOLOGY MARKET 2015-2024 ($ MILLION)
  • 2. GLOBAL NEUROLOGY MARKET 2015-2024 ($ MILLION)
  • 3. GLOBAL CARDIOLOGY MARKET 2015-2024 ($ MILLION)
  • 4. GLOBAL ANTIVIRAL MARKET 2015-2024 ($ MILLION)
  • 5. GLOBAL PSYCHIATRY MARKET 2015-2024 ($ MILLION)
  • 6. GLOBAL OTHERS MARKET 2015-2024 ($ MILLION)
  • 7. GLOBAL HOSPITALS MARKET 2015-2024 ($ MILLION)
  • 8. GLOBAL MOLECULAR DIAGNOSTIC LABORATORIES AND TESTING FACILITIES MARKET 2015-2024 ($ MILLION)
  • 9. GLOBAL ACADEMIC INSTITUTES, CLINICAL CARE AND RESEARCH LABORATORIES MARKET 2015-2024 ($ MILLION)
  • 10. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET 2015-2024 ($ MILLION)
  • 11. GLOBAL BIO AND HEALTH INFORMATICS COMPANIES MARKET 2015-2024 ($ MILLION)
  • 12. GLOBAL OTHERS MARKET 2015-2024 ($ MILLION)
  • 13. GLOBAL COMPANION DIAGNOSTICS MARKET 2015-2024 ($ MILLION)
  • 14. GLOBAL BIOMARKER IDENTIFICATION MARKET 2015-2024 ($ MILLION)
  • 15. GLOBAL HEALTH INFORMATICS MARKET 2015-2024 ($ MILLION)
  • 16. GLOBAL CLINICAL RESEARCH MARKET 2015-2024 ($ MILLION)
  • 17. UNITED STATES (U.S.) PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 18. CANADA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 19. UNITED KINGDOM (UK) PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 20. FRANCE PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 21. GERMANY PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 22. SPAIN PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 23. ROE PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 24. INDIA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 25. CHINA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 26. JAPAN PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 27. AUSTRALIA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 28. ROAPAC PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 29. LATIN AMERICA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
  • 30. MENA PERSONALIZED MEDICINE MARKET 2015-2024 ($ MILLION)
目次
Product Code: HPH-10640818

Global personalized medicine market is expected to rise with a CAGR of 12% over the forecast period 2017-2024. Key factors driving the market growth are rising prevalence of cancer, development of novel drugs, growth in biotechnology sector and growing number of companion/associated diagnostics. Stringent government regulations regarding product approval and high development costs are expected to restrain the market growth. However, increasing healthcare expenditure and favorable government policies and initiatives are expected to provide lucrative market opportunities. Complex nature of the drugs and presence of non-value based personalized medicine diagnostics reimbursement policy is expected to challenge the market growth.

Geographically, global personalized medicine market is segmented into North America, Europe, Asia Pacific and RoW. North America is the leading market region for global personalized medicine market in terms of market revenue share. Factors such as increasing research and development on the development of novel personalized medicine and drugs, growing biotechnology sector, rising government initiatives and support for the adoption of personalized medicine, etc. are driving the growth of North America personalized medicine market. However, Asia Pacific is expected to emerge as the fastest growing region during the forecast period 2017-2024 owing to the growing biopharmaceutical sector, rising healthcare spending, etc.

Global personalized medicine market is influenced by the presence of leading companies such as Becton, Dickinson and Company (U.S), GE Healthcare (U.S), Pfizer Inc. (U.S), Qiagen Inc. (The Netherlands), Vertex Pharmaceuticals Inc. (UK) and others. Product launch, joint venture, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

The report on global personalized medicine market includes therapeutic area, end user and applications. On the basis of therapeutic area, market is segmented into oncology, neurology, cardiology, antiviral, psychiatry and others. Neurology is the leading therapeutic area segment owing to the increase in research and development activities for the development of novel precision medicines for the cost-effective treatment of neurological disorders. On the basis of end users, market is segmented into hospitals, molecular diagnostic laboratories and testing facilities, academic institutes, clinical care and research laboratories, contract research organizations, bio and health informatics companies and others. Hospitals is the dominating end user segments due to the increased adoption of personalized medicines by the hospital patients for low cost personalized treatment. On the basis of applications of personalized medicine, market is segmented into companion diagnostics, biomarker identification, health informatics and clinical research. Biomarker identification is the leading application segment due to increased adoption of personalized medicines for the identification genes specific to the disease subtypes which would assist in the estimation of disease risk and therapy response.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL PERSONALIZED MEDICINE MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. KEY STRATEGIES & ANALYSIS
    • 2.8.2. MARKET SHARE ANALYSIS & TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING PREVALENCE OF CANCER
    • 3.1.2. DEVELOPMENT OF NOVEL DRUGS
    • 3.1.3. GROWTH IN BIOTECHNOLOGY SECTOR
    • 3.1.4. GROWING NUMBER OF COMPANION/ASSOCIATED DIAGNOSTICS
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. STRINGENT GOVERNMENT REGULATIONS REGARDING PRODUCT APPROVAL
    • 3.2.2. HIGH DEVELOPMENT COSTS
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. INCREASING HEALTHCARE EXPENDITURE
    • 3.3.2. FAVORABLE GOVERNMENT POLICIES AND INITIATIVES
  • 3.4. MARKET CHALLENGES
    • 3.4.1. COMPLEX NATURE OF THE DRUGS
    • 3.4.2. PRESENCE OF NON VALUE BASED PERSONALIZED MEDICINE DIAGNOSTICS REIMBURSEMENT POLICY

4. GLOBAL PERSONALIZED MEDICINE MARKET BY THERAPEUTIC AREA

  • 4.1. MARKET DEFINITION AND SCOPE
  • 4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. MARKET SEGMENTATION
    • 4.5.1. GLOBAL ONCOLOGY MARKET
      • 4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.1.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.1.4. KEY CONCLUSIONS
    • 4.5.2. GLOBAL NEUROLOGY MARKET
      • 4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.2.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.2.4. KEY CONCLUSIONS
    • 4.5.3. GLOBAL CARDIOLOGY MARKET
      • 4.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.3.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.3.4. KEY CONCLUSIONS
    • 4.5.4. GLOBAL ANTIVIRAL MARKET
      • 4.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.4.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.4.4. KEY CONCLUSIONS
    • 4.5.5. GLOBAL PSYCHIATRY MARKET
      • 4.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.5.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.5.4. KEY CONCLUSIONS
    • 4.5.6. GLOBAL OTHERS MARKET
      • 4.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 4.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 4.5.6.3. MARKET PARTICIPANTS AND PRODUCTS
      • 4.5.6.4. KEY CONCLUSIONS

5. GLOBAL PERSONALIZED MEDICINE MARKET BY END USER

  • 5.1. MARKET DEFINITION AND SCOPE
  • 5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 5.4. OPPORTUNITY MATRIX
  • 5.5. MARKET SEGMENTATION
    • 5.5.1. GLOBAL HOSPITALS MARKET
      • 5.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.1.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.1.4. KEY CONCLUSIONS
    • 5.5.2. GLOBAL MOLECULAR DIAGNOSTIC LABORATORIES AND TESTING FACILITIES MARKET
      • 5.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.2.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.2.4. KEY CONCLUSIONS
    • 5.5.3. GLOBAL ACADEMIC INSTITUTES, CLINICAL CARE AND RESEARCH LABORATORIES MARKET
      • 5.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.3.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.3.4. KEY CONCLUSIONS
    • 5.5.4. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET
      • 5.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.4.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.4.4. KEY CONCLUSIONS
    • 5.5.5. GLOBAL BIO AND HEALTH INFORMATICS COMPANIES MARKET
      • 5.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.5.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.5.4. KEY CONCLUSIONS
    • 5.5.6. GLOBAL OTHERS MARKET
      • 5.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 5.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 5.5.6.3. MARKET PARTICIPANTS AND PRODUCTS
      • 5.5.6.4. KEY CONCLUSIONS

6. GLOBAL PERSONALIZED MEDICINE MARKET BY APPLICATION

  • 6.1. MARKET DEFINITION AND SCOPE
  • 6.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.4. OPPORTUNITY MATRIX
  • 6.5. MARKET SEGMENTATION
    • 6.5.1. GLOBAL COMPANION DIAGNOSTICS MARKET
      • 6.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.1.3. MARKET PARTICIPANTS AND PRODUCTS
      • 6.5.1.4. KEY CONCLUSIONS
    • 6.5.2. GLOBAL BIOMARKER IDENTIFICATION MARKET
      • 6.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.2.3. MARKET PARTICIPANTS AND PRODUCTS
      • 6.5.2.4. KEY CONCLUSIONS
    • 6.5.3. GLOBAL HEALTH INFORMATICS MARKET
      • 6.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.3.3. MARKET PARTICIPANTS AND PRODUCTS
      • 6.5.3.4. KEY CONCLUSIONS
    • 6.5.4. GLOBAL CLINICAL RESEARCH MARKET
      • 6.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
      • 6.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
      • 6.5.4.3. MARKET PARTICIPANTS AND PRODUCTS
      • 6.5.4.4. KEY CONCLUSIONS

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIES
    • 7.1.1. LIST OF MERGERS AND ACQUISITION
    • 7.1.2. LIST OF JOINT VENTURES
    • 7.1.3. LIST OF PRODUCT LAUNCHES
    • 7.1.4. LIST OF PARTNERSHIPS

8. GEOGRAPHIC ANALYSIS

  • 8.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 8.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 8.3. OPPORTUNITY MATRIX
  • 8.4. GLOBAL PERSONALIZED MEDICINE MARKET BY REGION 2015-2024
    • 8.4.1. NORTH AMERICA
      • 8.4.1.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.1.2. TOP COUNTRY ANALYSIS
        • 8.4.1.2.1. U.S.
          • 8.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.1.2.1.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.1.2.1.3. KEY CONCLUSIONS
        • 8.4.1.2.2. CANADA
          • 8.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.1.2.2.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.1.2.2.3. KEY CONCLUSIONS
    • 8.4.2. EUROPE
      • 8.4.2.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.2.2. TOP COUNTRY ANALYSIS
        • 8.4.2.2.1. UK
          • 8.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.1.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.2.2.1.3. KEY CONCLUSIONS
        • 8.4.2.2.2. FRANCE
          • 8.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.2.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.2.2.2.3. KEY CONCLUSIONS
        • 8.4.2.2.3. GERMANY
          • 8.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.3.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.2.2.3.3. KEY CONCLUSIONS
        • 8.4.2.2.4. SPAIN
          • 8.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.4.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.2.2.4.3. KEY CONCLUSIONS
        • 8.4.2.2.5. REST OF EUROPE
          • 8.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.2.2.5.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.2.2.5.3. KEY CONCLUSIONS
    • 8.4.3. ASIA PACIFIC
      • 8.4.3.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.3.2. TOP COUNTRY ANALYSIS
        • 8.4.3.2.1. CHINA
          • 8.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.3.2.1.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.3.2.1.3. KEY CONCLUSIONS
        • 8.4.3.2.2. INDIA
          • 8.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.3.2.2.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.3.2.2.3. KEY CONCLUSIONS
        • 8.4.3.2.3. JAPAN
          • 8.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.3.2.3.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.3.2.3.3. KEY CONCLUSIONS
        • 8.4.3.2.4. AUSTRALIA
          • 8.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.3.2.4.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.3.2.4.3. KEY CONCLUSIONS
        • 8.4.3.2.5. REST OF ASIA PACIFIC
          • 8.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.3.2.5.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.3.2.5.3. KEY CONCLUSIONS
    • 8.4.4. ROW
      • 8.4.4.1. INDUSTRY ANALYSIS 2015-2024 ($ MILLION)
      • 8.4.4.2. TOP COUNTRY ANALYSIS
        • 8.4.4.2.1. LATIN AMERICA
          • 8.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.4.2.1.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.4.2.1.3. KEY CONCLUSIONS
        • 8.4.4.2.2. MIDDLE EAST & AFRICA
          • 8.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 ($ MILLION)
          • 8.4.4.2.2.2. MARKET PARTICIPANTS AND PRODUCTS
          • 8.4.4.2.2.3. KEY CONCLUSIONS

9. COMPANY PROFILES

  • 9.1. ABBOTT LABORATORIES (U.S.)
    • 9.1.1. OVERVIEW
    • 9.1.2. PRODUCT PORTFOLIO
    • 9.1.3. STRATEGIC INITIATIVES
    • 9.1.4. SCOT ANALYSIS
    • 9.1.5. STRATEGIC ANALYSIS
  • 9.2. ASURAGEN INCORPORATED (UK)
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. STRATEGIC INITIATIVES
    • 9.2.4. SCOT ANALYSIS
    • 9.2.5. STRATEGIC ANALYSIS
  • 9.3. ASTRA ZENECA PLC (UK)
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. STRATEGIC INITIATIVES
    • 9.3.4. SCOT ANALYSIS
    • 9.3.5. STRATEGIC ANALYSIS
  • 9.4. BECTON, DICKINSON AND COMPANY (U.S.)
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. STRATEGIC INITIATIVES
    • 9.4.4. SCOT ANALYSIS
    • 9.4.5. STRATEGIC ANALYSIS
  • 9.5. BIOGEN, INC. (U.S.)
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. STRATEGIC INITIATIVES
    • 9.5.4. SCOT ANALYSIS
    • 9.5.5. STRATEGIC ANALYSIS
  • 9.6. GE HEALTHCARE (U.S.)
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. STRATEGIC INITIATIVES
    • 9.6.4. SCOT ANALYSIS
    • 9.6.5. STRATEGIC ANALYSIS
  • 9.7. GLAXOSMITHKLINE PLC. (UK)
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. STRATEGIC INITIATIVES
    • 9.7.4. SCOT ANALYSIS
    • 9.7.5. STRATEGIC ANALYSIS
  • 9.8. ILLUMINA INCORPORATED (U.S.)
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. STRATEGIC INITIATIVES
    • 9.8.4. SCOT ANALYSIS
    • 9.8.5. STRATEGIC ANALYSIS
  • 9.9. MERCK & COMPANY, INC. (U.S.)
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. STRATEGIC INITIATIVES
    • 9.9.4. SCOT ANALYSIS
    • 9.9.5. STRATEGIC ANALYSIS
  • 9.10. NOVARTIS AG (SWITZERLAND)
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. STRATEGIC INITIATIVES
    • 9.10.4. SCOT ANALYSIS
    • 9.10.5. STRATEGIC ANALYSIS
  • 9.11. PFIZER INC. (U.S.)
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. STRATEGIC INITIATIVES
    • 9.11.4. SCOT ANALYSIS
    • 9.11.5. STRATEGIC ANALYSIS
  • 9.12. QIAGEN INC. (THE NETHERLANDS)
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. STRATEGIC INITIATIVES
    • 9.12.4. SCOT ANALYSIS
    • 9.12.5. STRATEGIC ANALYSIS
  • 9.13. ROCHE HOLDING AG (SWITZERLAND)
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. STRATEGIC INITIATIVES
    • 9.13.4. SCOT ANALYSIS
    • 9.13.5. STRATEGIC ANALYSIS
  • 9.14. SIEMENS HEALTHCARE (GERMANY)
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. STRATEGIC INITIATIVES
    • 9.14.4. SCOT ANALYSIS
    • 9.14.5. STRATEGIC ANALYSIS
  • 9.15. VERTEX PHARMACEUTICALS INC (UK)
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. STRATEGIC INITIATIVES
    • 9.15.4. SCOT ANALYSIS
    • 9.15.5. STRATEGIC ANALYSIS
Back to Top